Stock Trading Canary
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +1.7% | +1.7% | +1.7% |
| 20D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +8.0% | +8.0% | +8.0% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +7.6% | +7.6% | +7.6% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +5.1% | +5.1% | +5.1% |
COMPANY RESEARCH
ACTUATE THERAPEUTICS, INC.
ACTU · United States · Healthcare
Insider Signal
Snapshot: 05 Nov 2026 · 180-day research window
- Insider Signal
- 43.9 / 100 Research score, not a buy recommendation
- Reported buyers
- 1 180-day scoring window
- Net purchases
- 50.0k USD 180 days · purchases less sales
- Latest disclosure
- 2026-10-29 Publication date
What stands out
- SCHMITT DANIEL M accounts for 100% of comparable reported purchase value; buyer breadth and value are different measures.
- The share price fell 89.0% over 180 days; inspect disclosure dates before interpreting the purchases.
Price vs insider buying
ACTU · USD● Purchase × Sale ◇ Public disclosure ▥ 15-day cluster ·
Circles and crosses mark trade dates; diamonds below the axis mark later public disclosures. The trade became public on its disclosure date. Prices are nearest-session closes, not insider execution prices. Marker sizes are not compared when values or currencies differ.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (large purchases, bought in the last two weeks), while share price and trading argue against (price down over six months, price trails its sector). No data is held for: company actions.
- The insider purchases themselvesBulllarge purchases, bought in the last two weeks Bearone buyer only3 checked, under the threshold · 3 missing
- Share price and tradingBearprice down over six months, price trails its sector
- Short sellers2 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actionsno data held
Bull case · the buying is informative
- Net purchases of $50k equal 0.24% of the company's market value ($21.0M): large for the size of the business.
- The latest purchase is 8 days old (2026-10-28). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Only one insider bought. A single purchase can reflect that person's own finances rather than a view on the company.
- Share price and tradingThe share price is down 90% over six months (three months −70%, one month −55%) and stands 96% below its 52-week high. Insiders have bought into a fall the market has not reversed.
- Share price and tradingOver three months the share price changed −70% and the median of 220 Healthcare companies changed −18%: 52 points behind. The market has marked this company down against its own sector.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin <0.01%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- The 10b5-1 box of these Form 4 filings has not been read, so whether the purchases followed a pre-arranged plan is not known.
- Form 4 states the shares held after each trade. This site reads that from the SEC's quarterly data, which is published after a quarter ends, so it does not have it yet for these filings. Whether a purchase added 1% to a personal stake or doubled it is in the filing, not on this page.
Checked and under the threshold: 6, 1 close to it
- BearFINRA short interest on 2026-10-15 equals 4.7 days of average trading volume and 7.8% of the 24,014,202 shares outstanding, up 40% from the previous report. Counted for the bear side from 10 days, or from 10% of the shares outstanding. close to the threshold
- Either1 insider bought in the last 180 days and 0 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- BearNo insider sale is recorded in the same 180 days.
- BearOver the last 5 trading days to 2026-11-05, 47% of this stock's off-exchange volume was sold short; over the 60 days before, 56%. The market's median is 47%. This is trading volume, not a position: a market maker who sells short and covers the same day is counted, so about half of all volume is short on an ordinary day. It is shown for comparison and counts for neither side.
- BearNo insider filing in the last 180 days opened a hedge on this stock.
- BearProfit margin on the latest captured figures is <0.01%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Who is trading?
Named filings in 180 days. Purchase values are summed only when complete and in one currency.
| Insider | Transaction activity | Purchase value | Latest trade | Details | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCHMITT DANIEL MCEO / chair | 1 buy · 0 sell | 50.0k USD | 2026-10-28 | View transactions · 3
|
INSIDER SIGNAL
Score breakdown：43.9 / 100
1 insiders · 1 purchase events · $50k net purchases
US #741 · United States #741
WHY THIS SIGNAL?
Score anatomy
Each bar is that part's points in the score; the five parts add up to the score.
Number of buyers+7.0 / 35
How many different insiders bought within 15 days
Amount bought+5.2 / 25
The value bought, net of any insider sales
Buyers' roles+13.0 / 20
Lower in the company scores higher: in the backtest, purchases by the most senior insiders did worse
How recent+8.8 / 10
How long ago the latest purchase took place
Buying against selling+10.0 / 10
Lower when insiders also sold
What is holding the score back?
- ⚠ Few buyers · fewer than 4 different insiders
- ⚠ The amount bought is small on the score's scale
- ⚠ Buyers' roles add little · most senior buyer: President, CEO and Director; the most senior score lowest
- ✓ Recent buying · latest purchase 2026-10-28
Buyers' roles follow the US order of roles: CEOs, chairs and 10% owners score lowest.
Buying concentration
100%
Largest buyer：SCHMITT DANIEL M · 50k USD
Purchases counted, before sales：50k USD
The amount at the top of the page is purchases minus sales; this one counts purchases only, in the filing currency, so the two can differ. The score counts how many people bought; this shows separately who bought the most.
This is a ranking under the current US screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| SCHMITT DANIEL M | 0.355 USD | Oct 28, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 1 distinct reported filers
- Peak time window
- 2026-10-28 to 2026-10-28
- Current breadth input
- 0.200 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Latest purchase counted
SCHMITT DANIEL M · 50k USD · Price 0.355 USD · Oct 28, 2026 - 🔴 2 other line(s) are not counted, as they are not purchases the insider chose to make; 1 have a price of zero
Filing and data quality
These checks are auditable context; they do not change the rank or score.
- Identity match
- REVIEW
- Ticker / ISIN
- Ticker or ISIN missing
- Filing source links
- 6 / 6
- Median disclosure lag
- 0 days
- Latest disclosure age
- 7 days at snapshot
- Corrections / revisions
- 0
- Score-factor detail
- Saved
Insider timeline
One insider bought, once (28 Oct). The share closed at 0.38 that day and at 0.33 most recently (−14.6%).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
Blue line: this share's price, −89.0% over these six months
The closing price of each day, from 2.97 on 2026-05-11 to 0.33 on 2026-11-05. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, −9.6%
Taken from the 1610 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −89.0%, the typical one −9.6%, 79.4 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across United States disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases.
This company: insiders buying per month, last 12 months
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
1Oct
Nov
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since |
|---|---|---|---|---|---|---|
| SCHMITT DANIEL M | CEO / chair | 1 | — | 50.0k USD | 2026-10-28 | −14.6% |
Insiders' buying price vs the latest close
Insiders paid 0.3550 USD a share on average (1 purchase line, 1 buyer, 2026-10-28 – 2026-10-28). The close on 2026-11-05 was 7.9% below that price.
Prices paid are weighted by shares and taken from the filings; dividends are not counted. Not scored.
Buying size vs market trading
Complete price and volume history is not yet available.
Market-data coverage: 0 verified sessions · Latest session: — · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Sector context
- Buying breadth
- 4.1% (42 / 1,020 issuers)
- Sector rank
- #7 / 13
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − S&P 500 ETF (SPY adjusted close) return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +1.7% | +1.7% | +1.7% |
| 20D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +8.0% | +8.0% | +8.0% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +7.6% | +7.6% | +7.6% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +5.1% | +5.1% | +5.1% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +1.7% | +1.7% | +1.7% |
| 20D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +8.0% | +8.0% | +8.0% |
| 60D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +7.6% | +7.6% | +7.6% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +5.1% | +5.1% | +5.1% |
Signal outcomes
Calculated from immutable US ranking snapshots; excess return is stock return minus SPY return. Newly saved snapshots remain pending until each forward horizon matures. This never affects the US score.
| Horizon | Status | Result |
|---|---|---|
| 5D | Awaiting maturity | — |
| 20D | Awaiting maturity | — |
| 60D | Awaiting maturity | — |
| 120D | Awaiting maturity | — |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 100.7%
- Beta
- 1.20
- Avg daily volume
- $139,244.3
- 20-session drawdown
- -49.2%
- 60-session drawdown
- -81.6%
- Latest volume / prior median
- 1.5×
VALUATION
- Market cap
- $21.0M
- Market cap (EUR ref.)
- $18.7M
- P/E
- —
FUNDAMENTALS
- Revenue
- —
- Net income
- $-22.2M
- Operating profit
- $-22.5M
- Equity
- $7.9M
- Cash
- $13.2M
- Debt
- —
- Operating cash flow
- $-19.2M
- Free cash flow
- —
- Profit margin
- 0.0%
- ROE
- —
- Industry
- Biotechnology
Prices to 05 Nov 2026: price cache (yfinance). From OpenBB/yfinance, captured 05 Oct 2026: Market cap, Net income, Equity, Operating profit, Cash, Operating cash flow, Profit margin, Beta, Industry. ECB EUR reference rate dated 2026-11-05; it is not a trade-date conversion. It does not affect the insider score or rank.
Regulatory filings
- Insider filing announcement · published 2026-10-29 · trade date 2026-10-28
- Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
- Insider filing announcement · published 2026-02-13 · trade date 2026-02-13
Unfold all 4 filings
- Insider filing announcement · published 2026-10-29 · trade date 2026-10-28
- Insider filing announcement · published 2026-08-14 · trade date 2026-08-14
- Insider filing announcement · published 2026-02-13 · trade date 2026-02-13
- Insider filing announcement · published 2026-01-07 · trade date 2026-01-05
Results and insider purchases
No results announcement (8-K Item 2.02) from this company was found in its SEC filings.
Ownership and trading-plan context
| Direct / indirect ownership | Mixed direct / indirect |
|---|---|
| 10b5-1 filing evidence | Not declared in filing field |
| Evidence retrieved | 2026-11-03T00:16:28+00:00 |
These are accession-level filing fields. Unavailable means the evidence was not fetched or parsed; it is never inferred as “No” and does not adjust the US score.
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
1 qualifying purchase disclosure(s) · 1 transaction line(s)
Trade Oct 28, 2026Open market purchase
SCHMITT DANIEL M · President, CEO and Director
Published Oct 29, 2026 · Common Stock · 140844 shares × 0.355 USD · 49999.619999999995 USD
Open filingShowing 1 of 1 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 5 other transaction(s)
Trade Feb 13, 2026Shares withheld for tax or exercise price
SCHMITT DANIEL M · President, CEO and Director
Published Feb 13, 2026 · Common Stock · 121874.0 shares × 4.33 USD · 527714.42 USD
Open filingTrade Feb 13, 2026Exercise of derivative security
SCHMITT DANIEL M · President, CEO and Director
Published Feb 13, 2026 · Common Stock · 272055.0 shares × 0.0 USD · 0.0 USD
Open filingTrade Jan 5, 2026Open market sale
Kairos Venture Partners II, L.P.; THOMSON TODD S · Director,TenPercentOwner
Published Jan 7, 2026 · Common Stock · 280000.0 shares × 5.8 USD · 1624000.0 USD
Open filingUnfold all 2 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | 2026-08-14 | SCHMITT DANIEL M | President, CEO and Director | Shares withheld for tax or exercise price | Common Stock | 1.01 USD | USD | 120521.0 | 121726.21 USD | Open filing |
| 2026-08-14 | 2026-08-14 | SCHMITT DANIEL M | President, CEO and Director | Exercise of derivative security | Common Stock | 0.0 USD | USD | 272056.0 | 0.0 USD | Open filing |
Showing 5 of 5 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level $ aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Follow new disclosures
Subscribe to new United States disclosures. These are market-wide RSS feeds, not company-specific alerts.
Model & Sources
Signal history
43.9 / 100
Latest recorded score
↓ -0.3 ptssince the first recorded snapshot on 2026-11-03; 2 calendar days observed
- Recorded snapshots
- 3
- First snapshot
- 2026-11-03
There is not yet a 30-calendar-day comparison; earlier scores are not reconstructed. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Less than 30 days of comparable history is available, so factor movement is not yet decomposed.
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 44.2
- 44.0
- 43.9
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-11-03 | 44.2 |
| 2026-11-04 | 44.0 |
| 2026-11-05 | 43.9 |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.200 | 7.0 |
| Qualified-buy size | 25% | 0.207 | 5.2 |
| Role informativeness (inverted) | 20% | 0.650 | 13.0 |
| Recency | 10% | 0.875 | 8.8 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
Snapshot & identity
- Snapshot date
- 2026-11-05
- Ticker
- ACTU
- ISIN
- —
- Sector
- Healthcare
- Industry
- —
Company logos by Parqet
How to read Form 4 transaction codes
| Code | Interpretation | Screen treatment |
|---|---|---|
| P | Open-market / private purchase | Buy evidence when the security is qualifying equity |
| S | Sale | Sell evidence when the security is qualifying equity |
| A | Grant / award | Context only |
| F | Tax-related withholding | Context only |
| M | Option exercise | Context only |
| G | Gift | Context only |
| J / L | Other / non-directional | Context only |
P/S rows for options, warrants, compensation units and debt remain visible for audit but are excluded from equity scores and quotes.